Abstract
Introduction Parkinson’s Disease (PD) is a neurodegenerative disorder that affects motor and non-motor functions. Speech impairments, such as reduced variability in pitch (F0SD) and intensity (IntSD), are commonly observed. Early identification of these changes through voice biomarkers offers a noninvasive approach for detecting PD, tracking disease progression, and investigating the effects of interventions on this population. This study investigates the impact of dance on people with PD voice features over a five-year period and explores whether dance interventions can mitigate these impairments.
Methods A longitudinal dance program involved 29 individuals with PD and 29 healthy controls. Voice recordings were collected before and after dance sessions over five years (2014-2019) and analyzed using machine learning models to extract F0SD and IntSD. Statistical analyses, including ANOVA and mixed-effect models, were performed using R studio to evaluate group differences, longitudinal changes, and the effects of dance on voice parameters.
Results The analysis revealed a significant main effect of time on F0SD, indicating measurable changes over the study period. However, the interaction between group and time was not statistically significant, suggesting similar trends in both groups. While the PD group did not exhibit the expected decline in F0SD seen in previous studies, IntSD remained largely unchanged, suggesting it may be less responsive to intervention.
Conclusion These findings demonstrate the potential of F0SD and IntSD as biomarkers for tracking PD progression. Dance interventions provide measurable benefits for F0SD, though further research is needed to determine optimal intervention duration and explore additional speech features such as jitter, shimmer, HNR, and CPP. Early and targeted interventions, such as combining dance with speech therapy, may enhance communication abilities and improve the quality of life for individuals with PD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
A Parkinson Canada Pilot grant was received by Joseph FX DeSouza; Joseph FX DeSouza is funded by a National Science and Engineering Research Council (NSERC) Discovery Grant (2017-05647), as well as donations from the Irpinia Club of Toronto and others.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human Participants Review Committee (HPRC), Office of Research Ethics, York University granted ethical approval. The study received initial ethics approval under Certificate Numbers 2013-211 and 2017-296. For the current study, a renewed ethics approval-granted to Professor Joseph DeSouza-was used, covering the ongoing research (Certificate#: 2017-296 renewed on September 22, 2022, by the York University Office of Research Ethics).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.